| http://purl.uniprot.org/citations/21953571 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/21953571 | http://www.w3.org/2000/01/rdf-schema#comment | "Trastuzumab emtansine (T-DM1) is a HER2-targeted antibody-drug conjugate in development for treatment of HER2-positive cancers. T-DM1 has been tested as a single agent in a phase I and 2 phase II studies of patients with heavily pretreated metastatic breast cancer (MBC), with the maximum tolerated dose established at 3.6 mg/kg intravenously for every-3-week dosing. The authors present results from the population pharmacokinetics analysis for T-DM1. Population pharmacokinetics for T-DM1 were characterized using a clinical database of 273 patients from the 3 studies. Pharmacokinetics was best described by a linear 2-compartment model. Population estimates (interindividual variability [IIV]) for pharmacokinetic parameters were clearance, 0.7 L/d (21.0%); central compartment volume (V(c)), 3.33 L (13.2%); peripheral compartment volume (V(p)), 0.89 L (50.4%); and intercompartmental clearance, 0.78 L/d. Body weight, albumin, tumor burden, and aspartate aminotransferase levels were identified as statistically significant covariates accounting for interindividual variability in T-DM1 pharmacokinetics, with body weight having a greater effect on IIV of clearance and V(c) than other covariates. T-DM1 exposure was relatively consistent across the weight range following body weight-based dosing. This analysis suggests no further T-DM1 dose adjustments are necessary in heavily pretreated patients with MBC."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.org/dc/terms/identifier | "doi:10.1177/0091270011403742"xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Gupta M."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Wang B."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Joshi A."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Modi S."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Chu Y.W."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Yi J.H."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Burris H.A."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Girish S."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Klencke B."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Lorusso P.M."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Agresta S."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/author | "Beeram M."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/date | "2012"xsd:gYear |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/name | "J Clin Pharmacol"xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/pages | "691-703"xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/title | "Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer."xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://purl.uniprot.org/core/volume | "52"xsd:string |
| http://purl.uniprot.org/citations/21953571 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/21953571 |
| http://purl.uniprot.org/citations/21953571 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/21953571 |
| http://purl.uniprot.org/uniprot/#_A0A8A0Y2Q6-mappedCitation-21953571 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/21953571 |
| http://purl.uniprot.org/uniprot/#_A0A0R9RWK2-mappedCitation-21953571 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/21953571 |
| http://purl.uniprot.org/uniprot/#_E2I6F8-mappedCitation-21953571 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/21953571 |